Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 17/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.64 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.64 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.64 |
| ▸ | TPH1 | P17752 | 1/20 | 0.54 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446900 | 0.85 | ADORA2B (0.70) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL15642922 | 0.84 | ADORA2B (0.60) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343680 | 0.83 | ADORA2B (0.68) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1446898 | 0.83 | ADORA2B (0.69) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL32660827 | 0.82 | ADORA2B (0.69) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343076 | 0.82 | ADORA2B (0.66) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343071 | 0.81 | ADORA2B (0.65) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL839824 | 0.80 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343062 | 0.80 | ADORA2B (0.66) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL30728922 | 0.80 | ADORA2B (0.66) | ADORA2BADORA2AADORA1ADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595630-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012003220-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | claimed |
| EP-2694074-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2595630-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012154340-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012003220-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |